// App-Quantinova.ai

: Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210.

Researchers

Presenter

  • Nancy S. Vander Velde

Principal Investigators

  • Annie Guerin

  • Raluca Ionescu-Ittu

  • Sherry Shi

  • Eric Wu

  • Shih-Wen Lin

  • Ling-I Hsu

  • Kai-Uwe Saum

  • Sabine De Ducla

  • Jingjing Wang

  • Shi Li

  • Christina Louise Derleth

  • Shuqian Liu

  • Lizheng Shi

  • John Leppert

Medical Centers

  • Southeast Louisiana Veterans Health Care Services, New Orleans, LA

  • Analysis Group, Inc., Montreal, QC, Canada

  • Analysis Group, Inc., Boston, MA

  • Genentech, Inc., South San Francisico, CA

  • Roche Pharma AG, Grenzach-Wyhlen, Germany

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Southeast Louisiana Veterans Health Care Services, New Orleans, LA

  • Tulane University, New Orleans, LA

  • Veterans Affairs Palo Alto Health Care System, Palo Alto, CA

Locations

  • United States

  • Canada

Companies

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02951767

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved